Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5045364 | 0.91 | THRA (0.48) | THRATHRB | |
| SCHEMBL14264305 | 0.83 | THRA (0.49) | THRATHRB | |
| SCHEMBL5042748 | 0.81 | THRA (0.44) | THRATHRB | |
| SCHEMBL5038181 | 0.81 | THRA (0.47) | THRATHRB | |
| SCHEMBL5042151 | 0.78 | THRA (0.51) | THRATHRB | |
| SCHEMBL5042857 | 0.76 | THRA (0.41) | THRATHRB | |
| SCHEMBL5560966 | 0.74 | THRA (0.48) | THRATHRB | |
| SCHEMBL14264304 | 0.74 | THRA (0.42) | THRATHRB | |
| SCHEMBL5041618 | 0.73 | THRA (0.45) | THRATHRB | |
| SCHEMBL5041164 | 0.71 | THRA (0.45) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1601641-A4 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1601641-A2 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | Bristol-Myers Squibb Company (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040180940-A1 | Substituted anilide ligands for the thyroid receptor | KARO BIO AB (SE) | 2004-09-16 | — | — | US | disclosed |
| WO-2004067482-A2 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180940-A1 | Substituted anilide ligands for the thyroid receptor | TSHR, TRHR, THRA | THRA 3/4885THRB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.